February 20, 2007: Prempro Plaintiff Awarded $3M
A Philadelphia jury has found sufficient evidence that an Ohio woman's breast cancer was caused by her use of the hormone replacement drug Prempro, and is ordering Prempro manufacturer Wyeth to pay the plaintiff $3 million in damages. The jury also ruled that Wyeth failed to provide adequate warnings of Prempro use risks. The verdict came after a mistrial was declared in the same case in October 2006.
February 15, 2007: Arkansas Jury Rules in Wyeth's Favor
A jury in Little Rock, Arkansas has cleared Wyeth of liability in a trial over the safety of the drug company's hormone replacement drugs Prempro and Premarin. The plaintiff, Helene Rush, had blamed Wyeth's estrogen-progestin therapy drugs for the development of her breast cancer, and claimed that she and her doctors were unaware of any health risks that could result from the use of the drugs.
September 15, 2006: Wyeth Not Liable in First Prempro Trial
After deliberating for 4 days, the jury in the first trial over the safety of Prempro cleared hormone replacement drug maker Wyeth of any liability for a 67 year-old woman's breast cancer, finding that Wyeth adequately warned patients of Prempro's risks. The federal case in Little Rock, Arkansas was the first of approximately 5,000 Prempro lawsuits to go to trial.
August 23, 2006: Opening Statements in First Prempro Trial
Opening statements began in the first trial over the safety of hormone replacement therapy drug Prempro, in federal court in Little Rock, Arkansas. The plaintiff, who developed breast cancer after taking Prempro for eight years, alleges that Prempro manufacturer Wyeth repeatedly ignored evidence that the drug might cause cancer. The trial is the first in about 5,000 Prempro lawsuits nationwide.
March 2, 2004: Early Findings in "Estrogen Alone" Study: Stroke Risk
After conclusion of the first phase of an "estrogen alone" study under the Women's Health Initiative (WHI), the National Institutes of Health (NIH) states that while estrogen treatment alone does not appear to decrease (or increase) the risk of heart disease, it does appear to increase the risk of stroke. The study was designed to assess certain long-term risks of estrogen replacement treatments, and did not include specific testing of medications such as Prempro, which contain a combination of estrogen and progestin. Read the press release from the NIH.
February 20, 2004: Wyeth Announces "Lowest Effective Dose" Prempro
Wyeth Pharmaceuticals, manufacturer of the combination hormone replacement therapy treatment Prempro, announced the widespread market availability of the "lowest effective dose" version of the drug. In a press release, Wyeth reiterated the U.S. Food and Drug Administration's (FDA's) opinion that women should use the lowest effective dose of hormone therapy for the shortest duration. Read the press release from Wyeth.
May 27, 2003: Study Finds Increased Risk of Dementia in HRT Patients
A study under the Women's Health Initiative (WHI) of the National Institutes of Health (NIH) found that older women receiving Prempro combination hormone replacement therapy (HRT) experienced twice the rate of dementia when compared to women not receiving the therapy. Read the press release from the NIH.
March 13, 2003: FDA Approves Lower Dose of Prempro
The FDA approved a lower dose single tablet of Prempro for women suffering from symptoms of menopause. In a press release, the FDA cautioned that while hormone replacement therapy can provide some benefit, "these treatments also have important risks, and should be used in the lowest dose and for the least duration required to provide relief." Read the press release from the FDA.
Contact a qualified product liability attorney to make sure your rights are protected.